Disease · MONDO_0043797
Comparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 23
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pregabalin vs Placebo: serious adverse events | 9 of 112 | 10 of 107 | 219 | NCT00407745 | Trial comparisons |
| Pregabalin vs Placebo: Number of Participants With >=30% Reduction in Weekly Mean Pain Score From Baseline | 48 of 105 | 33 of 105 | 210 | NCT00407745 | Trial comparisons |
| Pregabalin vs Placebo: Number of Participants With >=50% Reduction in Weekly Mean Pain Score From Baseline | 31 of 105 | 16 of 105 | 210 | NCT00407745 | Trial comparisons |
| Pregabalin vs Placebo: Number of Participants Having Optimal Sleep Based on Medical Outcomes Study Sleep Scale (MOS-SS) | 49 of 100 | 30 of 99 | 199 | NCT00407745 | Trial comparisons |
| Pregabalin vs Placebo: Number of Participants With Improvement in the Number of Attacks Based on NPSI - Number of Attacks (Item 7) | 48 of 100 | 38 of 99 | 199 | NCT00407745 | Trial comparisons |
| Pregabalin vs Placebo: Number of Participants With Improved Duration of Brief Pain Attacks Based on NPSI - Duration (Item 4) | 39 of 100 | 28 of 97 | 197 | NCT00407745 | Trial comparisons |
| ZA Infusion Arm vs Rowing Arm: serious adverse events | 6 of 26 | 6 of 19 | 45 | NCT01426555 | Trial comparisons |
| Lithium Carbonate Tablet vs Placebo: serious adverse events | 0 of 20 | 0 of 20 | 40 | NCT00750061 | Trial comparisons |
| Active Drug vs Placebo: serious adverse events | 1 of 22 | 0 of 18 | 40 | NCT00755079 | Trial comparisons |
| Experimental Group vs Control Group: deaths from any cause | 0 of 21 | 0 of 19 | 40 | NCT05639946 | Trial comparisons |
| Experimental Group vs Control Group: serious adverse events | 0 of 21 | 0 of 19 | 40 | NCT05639946 | Trial comparisons |
| RT+Tp vs Testosterone Replacement Patches (Tp): deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT01652040 | Trial comparisons |
| RT+Tp vs Testosterone Replacement Patches (Tp): serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT01652040 | Trial comparisons |
| Experimental Group vs Control Group: deaths from any cause | 0 of 11 | 0 of 11 | 22 | NCT02441660 | Trial comparisons |
| Experimental Group vs Control Group: serious adverse events | 0 of 11 | 0 of 11 | 22 | NCT02441660 | Trial comparisons |
| Brivaracetam Group vs Control Group: deaths from any cause | 0 of 11 | 0 of 9 | 20 | NCT04379011 | Trial comparisons |
| Brivaracetam Group vs Control Group: serious adverse events | 1 of 11 | 0 of 9 | 20 | NCT04379011 | Trial comparisons |
| Botulinum Toxin A vs Placebo: deaths from any cause | 0 of 8 | 0 of 8 | 16 | NCT02736890 | Trial comparisons |
| Botulinum Toxin A vs Placebo: serious adverse events | 1 of 8 | 0 of 8 | 16 | NCT02736890 | Trial comparisons |
| Testosterone and LPWS vs Testosterone and Standard NMES: deaths from any cause | 0 of 6 | 0 of 6 | 12 | NCT03345576 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0043797/comparisons